|
US6297239B1
(en)
|
1997-10-08 |
2001-10-02 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
|
US6566372B1
(en)
|
1999-08-27 |
2003-05-20 |
Ligand Pharmaceuticals Incorporated |
Bicyclic androgen and progesterone receptor modulator compounds and methods
|
|
US6462076B2
(en)
|
2000-06-14 |
2002-10-08 |
Hoffmann-La Roche Inc. |
Beta-amino acid nitrile derivatives as cathepsin K inhibitors
|
|
DE60131423T2
(de)
|
2000-09-08 |
2009-03-19 |
Prozymex A/S |
Ratten-spezifische cathepsin, dipeptidyl peptidase i (dppi): kristallstruktur, hemmstoffe und deren anwendungen
|
|
US20110236367A1
(en)
|
2000-09-08 |
2011-09-29 |
Telenav, Inc. |
Rat cathespin dipeptidyl peptidase i (dppi): crystal structure and its uses
|
|
EP1217000A1
(en)
|
2000-12-23 |
2002-06-26 |
Aventis Pharma Deutschland GmbH |
Inhibitors of factor Xa and factor VIIa
|
|
JP2005517640A
(ja)
|
2001-12-04 |
2005-06-16 |
エフ．ホフマン−ラ ロシュ アーゲー |
置換２−アミノ−シクロアルカンカルボキサアミドならびにシステインプロテアーゼインヒビターとしてのその使用
|
|
US20040253311A1
(en)
|
2002-12-18 |
2004-12-16 |
Roger Berlin |
Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
|
|
WO2004076434A1
(en)
|
2003-02-28 |
2004-09-10 |
Aic |
Dipeptidyl peptidase inhibitors
|
|
US7893096B2
(en)
|
2003-03-28 |
2011-02-22 |
Novartis Vaccines And Diagnostics, Inc. |
Use of small molecule compounds for immunopotentiation
|
|
ATE399763T1
(de)
|
2003-05-30 |
2008-07-15 |
Prozymex As |
Proteasehemmer
|
|
JP2006527704A
(ja)
|
2003-06-18 |
2006-12-07 |
プロザイメックス・アクティーゼルスカブ |
プロテアーゼ阻害剤
|
|
JP5301152B2
(ja)
|
2004-04-07 |
2013-09-25 |
ライナット ニューロサイエンス コーポレイション |
神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法
|
|
EP2017620A3
(en)
|
2004-04-28 |
2009-04-22 |
Bayer HealthCare AG |
Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (DPP1)
|
|
US7618981B2
(en)
|
2004-05-06 |
2009-11-17 |
Cytokinetics, Inc. |
Imidazopyridinyl-benzamide anti-cancer agents
|
|
GEP20094671B
(en)
*
|
2004-06-29 |
2009-04-27 |
Nycomed Danmark Aps |
Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention
|
|
CN103251953A
(zh)
|
2004-07-19 |
2013-08-21 |
约翰·霍普金斯大学 |
供免疫抑制的flt3抑制剂
|
|
SI1853250T1
(sl)
|
2005-02-18 |
2012-01-31 |
Abraxis Bioscience Llc |
Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
|
|
WO2007005668A2
(en)
|
2005-06-30 |
2007-01-11 |
Amgen Inc. |
Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
|
|
AU2008223348A1
(en)
|
2007-03-07 |
2008-09-12 |
Alantos Pharmaceuticals Holding, Inc. |
Metalloprotease inhibitors containing a heterocyclic moiety
|
|
TW200916447A
(en)
|
2007-08-29 |
2009-04-16 |
Methylgene Inc |
Sirtuin inhibitors
|
|
BRPI0817311A2
(pt)
|
2007-09-25 |
2015-03-17 |
Novartis Ag |
Tratamento de doenças pulmonares com medicamentos em aerossol tais como a vancomicina
|
|
WO2009074829A1
(en)
|
2007-12-12 |
2009-06-18 |
Astrazeneca Ab |
Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors
|
|
US9315449B2
(en)
|
2008-05-15 |
2016-04-19 |
Duke University |
Substituted pyrazoles as heat shock transcription factor activators
|
|
PE20100252A1
(es)
|
2008-06-06 |
2010-04-12 |
Boehringer Ingelheim Int |
Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
|
|
CA2746220A1
(en)
|
2008-12-08 |
2010-07-08 |
Vm Pharma Llc |
Compositions of protein receptor tyrosine kinase inhibitors
|
|
RU2550133C2
(ru)
|
2009-04-01 |
2015-05-10 |
БИАЛ-ПОРТЕЛА энд КА., С.А. |
Фармацевтические составы, включающие производные нитрокатехола, и способы их получения
|
|
CN102574830A
(zh)
|
2009-05-07 |
2012-07-11 |
阿斯利康(瑞典)有限公司 |
取代的1-氰基乙基杂环基甲酰胺化合物750
|
|
WO2010142985A1
(en)
|
2009-06-10 |
2010-12-16 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
|
|
JP2013523833A
(ja)
*
|
2010-04-07 |
2013-06-17 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
|
|
WO2011154677A1
(en)
|
2010-06-09 |
2011-12-15 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
|
|
WO2012119941A1
(en)
|
2011-03-04 |
2012-09-13 |
Prozymex A/S |
Peptidyl nitrilcompounds as peptidase inhibitors
|
|
US8999975B2
(en)
|
2011-09-19 |
2015-04-07 |
Boehringer Ingelheim International Gmbh |
Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
|
|
CA2863723C
(en)
|
2012-02-21 |
2020-09-22 |
Carl Deutsch |
8-substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors
|
|
ES2644965T3
(es)
|
2012-04-17 |
2017-12-01 |
Astellas Pharma Inc. |
Compuesto heterocíclico aromático bicíclico nitrogenado
|
|
WO2014091443A1
(en)
|
2012-12-13 |
2014-06-19 |
Glaxo Group Limited |
Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
|
|
EP2775304A1
(en)
|
2013-03-07 |
2014-09-10 |
Universitätsspital Basel |
Methods for detecting inflammatory disorder
|
|
JP6441831B2
(ja)
|
2013-03-14 |
2018-12-19 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
カテプシンｃの置換２−アザ−ビシクロ［２．２．２］オクタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
|
|
JP6437929B2
(ja)
|
2013-03-14 |
2018-12-12 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
カテプシンｃの置換二環式１−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
|
|
PE20151727A1
(es)
|
2013-03-14 |
2015-12-17 |
Boehringer Ingelheim Int |
Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
|
|
US8871783B2
(en)
|
2013-03-14 |
2014-10-28 |
Boehringer Ingelheim International Gmbh |
Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin C
|
|
UY35400A
(es)
|
2013-03-15 |
2014-10-31 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de enfermedades parasitarias
|
|
JP6473738B2
(ja)
|
2013-04-01 |
2019-02-20 |
パルマトリックス，インコーポレイテッド |
チオトロピウム乾燥粉末
|
|
US10670594B2
(en)
|
2013-08-22 |
2020-06-02 |
Emory University |
Devices and methods related to airway inflammation
|
|
WO2015032943A1
(en)
|
2013-09-09 |
2015-03-12 |
Prozymex A/S |
Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
|
|
WO2015032942A1
(en)
|
2013-09-09 |
2015-03-12 |
Prozymex A/S |
N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
|
|
GB201400034D0
(en)
*
|
2014-01-02 |
2014-02-19 |
Astrazeneca Ab |
Pharmaceutical Compositions comprising AZD9291
|
|
NO2699580T3
(https=)
|
2014-01-24 |
2018-02-24 |
|
|
|
GB201402070D0
(en)
*
|
2014-02-07 |
2014-03-26 |
Galapagos Nv |
Pharmaceutical compositions for the treatment of inflammatory disorders
|
|
MX2016013245A
(es)
*
|
2014-04-10 |
2017-01-16 |
Novartis Ag |
Regimen de dosificacion de liberacion inmediata de moduladores s1p.
|
|
SMT202000516T1
(it)
|
2014-05-15 |
2020-11-10 |
Insmed Inc |
Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari
|
|
EP3149192B1
(en)
|
2014-05-30 |
2019-01-02 |
Versitech Limited |
Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
|
|
JP6529575B2
(ja)
|
2014-08-01 |
2019-06-12 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
|
|
KR102510588B1
(ko)
|
2014-09-12 |
2023-03-17 |
베링거 인겔하임 인터내셔날 게엠베하 |
카텝신 c의 스피로사이클릭 억제제
|
|
CA2965566A1
(en)
|
2014-11-14 |
2016-05-19 |
Boehringer Ingelheim International Gmbh |
Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists
|
|
DK3265452T3
(en)
|
2015-03-05 |
2020-06-08 |
Neuprozyme Therapeutics ApS |
Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
|
|
KR20250107292A
(ko)
|
2016-07-29 |
2025-07-11 |
인스메드 인코포레이티드 |
기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
|
|
AU2019217870A1
(en)
|
2018-02-07 |
2020-08-27 |
Insmed Incorporated |
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating ANCA associated vasculitides
|
|
KR20250002710A
(ko)
|
2018-03-01 |
2025-01-07 |
아스트라제네카 에이비이 |
(2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물
|
|
US20210252015A1
(en)
|
2018-07-17 |
2021-08-19 |
Insmed Incorporated |
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease
|
|
AU2019306532A1
(en)
|
2018-07-17 |
2021-03-04 |
Insmed Incorporated |
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
|
|
WO2020214855A1
(en)
|
2019-04-17 |
2020-10-22 |
Azora Therapeutics, Inc. |
Topical compositions and methods for treating inflammatory skin diseases
|
|
EA202193251A1
(ru)
|
2019-06-05 |
2022-03-10 |
Эмори Юниверсити |
Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций
|
|
WO2022140516A1
(en)
|
2020-12-22 |
2022-06-30 |
Insmed Incorporated |
Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
|
|
CN112920124B
(zh)
|
2021-01-29 |
2024-03-01 |
安徽医科大学 |
一种嘧啶-2,4-二胺类化合物及其制备方法与应用
|
|
WO2022232420A1
(en)
|
2021-04-29 |
2022-11-03 |
Insmed Incorporated |
Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
|
|
US20240226112A1
(en)
|
2021-04-29 |
2024-07-11 |
Insmed Incorporated |
Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
|
|
US20250049813A1
(en)
|
2021-10-29 |
2025-02-13 |
Insmed Incorporated |
Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
|
|
EP4479059A4
(en)
|
2022-02-16 |
2026-01-28 |
Insmed Inc |
CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVE
|